Why the study?
Does targeting hypercontractility and oxidative stress through myosin inhibition reduce arrhythmic risk in hypertrophic cardiomyopathy models?
Does targeting hypercontractility and oxidative stress through myosin inhibition reduce arrhythmic risk in hypertrophic cardiomyopathy models?
This preclinical study demonstrates a mechanistic link between hypercontractility, mitochondrial reactive oxygen species, and creatine kinase dysfunction in HCM, suggesting myosin inhibition may restore energy balance and reduce arrhythmic risk.
BACKGROUND: disrupt CK function in HCM. METHODS: sensitizer EMD-57033, the CK inhibitor 1-fluoro-2,4-dinitrobenzene (DNFB), and the myosin inhibitor MYK-581, a mavacamten derivative. RESULTS: levels and triggered cellular arrhythmias. This mitochondrial oxidation was independently confirmed in mito-roGFP2-Orp1 cardiomyocytes exposed to DNFB. Mitochondrial-targeted catalase-overexpressing mice were protected from DNFB-induced oxidative stress and arrhythmogenic events. CONCLUSIONS: This study reveals a mechanistic link between hypercontractility, mitochondrial reactive oxygen species, and CK dysfunction in HCM, perpetuating a cycle of energetic dysfunction. Targeting hypercontractility and oxidative stress through myosin inhibition offers a strategy to restore energy balance and reduce arrhythmic risk in HCM.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: